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Background
The European orphan legislative framework has been
successful in delivering approved new treatments since
its establishment in 2000. But the data needed to reach a
positive risk-benefit analysis for regulatory approval often
falls short of that needed by Member States to justify
reimbursed availability to patients. This gap leads to dif-
ferences in availability of new orphan medicines. The
CAVOD proposals build on more than 12 years of formal
collaborative approaches to European orphan drug pol-
icy, which have consistently agreed on the need to gather
and share information at a European level. They would
establish a process for the exchange of knowledge from
the earliest stage in a drug’s development, through to in-
life outcomes after a treatment is available to patients,
with the objective of bundling fragmented know-how to
allow the timely production of well-informed decisions
on national pricing and reimbursement, while respecting
existing roles, responsibilities and competences.
Methodology and content
The approach intends to optimise processes, notably at
four key time points. All activities should be based on
existing and planned roles, responsibilities and legislative
frameworks, and in collaboration between all parties
involved at Member State and EU level, including regula-
tors, HTA bodies, payers, patients and the sponsor. Early
dialogue between the EMA, regulators and HTA bodies
should be instigated at the time of orphan designation and
the assumption of significant benefit. This should continue
through protocol assistance to the Marketing Authorisa-
tion and confirmation of the significant benefit. Between
the CHMP opinion and the granting of the Marketing
Authorisation, the available information on a drug should
be gathered in a useable form and additional information
requirements defined, together with a plan for develop-
ment to be undertaken by the Marketing Authorisation
Holder. This will give HTA bodies access to the widest
pool of in-use data on a pan-European basis, although the
appropriate methodological tools to evaluate orphan drugs
will need to be developed.
Proposed results
It is intended that the collaboration at European level on
the clinical added value of an orphan medicinal product
will bridge the gap of data generation and availability
between what is needed to reach a positive risk-benefit
analysis and what is needed to facilitate understanding of
the appropriate positioning of a product in the therapeutic
arsenal for a given rare condition within national health-
care systems. This should be a voluntary process carried
out on a case-by-case basis. Uptake will be a key measure
of success, because use of the system will largely depend
on its ability to deliver a more streamlined approach.
Implementation could start already where the elements
are in place, while additional required elements are being
developed.
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